Aaron B Waxman

List of Publications by Year
in descending order

149 papers	7,289 citations	50276 46 h-index	60623 81 g-index
156 all docs	156 docs citations	156 times ranked	7675 citing authors

#	Article	IF	Citations
1	Persistent Exertional Intolerance After COVID-19. Chest, 2022, 161, 54-63.	0.8	186
2	Group 1 Clinical Features and Treatment. , 2022, , 616-632.		0
3	Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 198-207.	5.6	32
4	Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Chest, 2022, 162, 1116-1126.	0.8	10
5	Recent advances in the management of pulmonary hypertension with interstitial lung disease. European Respiratory Review, 2022, 31, 210220.	7.1	13
6	Systemic vascular distensibility relates to exercise capacity in connective tissue disease. Rheumatology, 2021, 60, 1429-1434.	1.9	6
7	Ranolazine Improves Right Ventricular Function in Patients With Precapillary Pulmonary Hypertension: Results From a Double-Blind, Randomized, Placebo-Controlled Trial. Journal of Cardiac Failure, 2021, 27, 253-257.	1.7	22
8	Arterial vascular volume changes with haemodynamics in schistosomiasis-associated pulmonary arterial hypertension. European Respiratory Journal, 2021, 57, 2003914.	6.7	3
9	Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study. Pulmonary Circulation, 2021, 11, 204589402199929.	1.7	1
10	Pulmonary Hypertension: An Integrative Approach to Assessment and Management. Clinics in Chest Medicine, 2021, 42, xiii-xiv.	2.1	0
11	Inspiratory flow patterns with dry powder inhalers of low and medium flow resistance in patients with pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-10.	1.7	5
12	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2021, 384, 1204-1215.	27.0	224
13	Sex-Related Differences in Dynamic Right Ventricular-Pulmonary Vascular Coupling in Heart Failure With Preserved Ejection Fraction. Chest, 2021, 159, 2402-2416.	0.8	13
14	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respiratory Medicine,the, 2021, 9, 1266-1274.	10.7	62
15	A Woman with a Repaired Atrial Septal Defect and Pulmonary Hypertension with Worsening Dyspnea. Annals of the American Thoracic Society, 2021, 18, 1052-1058.	3.2	0
16	Quantification of Arterial and Venous Morphologic Markers in Pulmonary Arterial Hypertension Using CT Imaging. Chest, 2021, 160, 2220-2231.	0.8	13
17	A Novel Protective Role for Matrix Metalloproteinase-8 in the Pulmonary Vasculature. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1433-1451.	5.6	11
18	Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. Circulation: Cardiovascular Imaging, 2021, 14, e012347.	2.6	9

#	Article	IF	Citations
19	Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. New England Journal of Medicine, 2021, 384, 325-334.	27.0	292
20	Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis. Journal of Heart and Lung Transplantation, 2020, 39, 289-299.	0.6	19
21	Dynamic right ventricular function response to incremental exercise in pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-8.	1.7	14
22	Fick principle and exercise pulmonary hemodynamic determinants of the sixâ€minute walk distance in pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-9.	1.7	6
23	Clinical trials in group 3 pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2020, 26, 391-396.	2.6	5
24	Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease. Chest, 2020, 158, 350-358.	0.8	9
25	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease. Circulation: Heart Failure, 2020, 13, e006363.	3.9	27
26	The Failing Right Heart from Pulmonary Hypertension. Clinical Cases in Cardiology, 2020, , 147-169.	0.0	0
27	Pulmonary Vascular Distensibility and Early Pulmonary Vascular Remodeling in Pulmonary Hypertension. Chest, 2019, 156, 724-732.	0.8	38
28	Metabolomics of exercise pulmonary hypertension are intermediate between controls and patients with pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-10.	1.7	12
29	Unexplained exertional intolerance associated with impaired systemic oxygen extraction. European Journal of Applied Physiology, 2019, 119, 2375-2389.	2.5	28
30	Dynamic right ventricularâ€“pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-10.	1.7	36
31	Right Ventricular-Arterial Uncoupling During Exercise in Heart Failure With Preserved Ejection Fraction. Chest, 2019, 156, 933-943.	0.8	32
32	Anatomic Relationship of the Complex Tricuspid Valve, Right Ventricle, and Pulmonary Vasculature. JAMA Cardiology, 2019, 4, 478.	6.1	43
33	BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension. Circulation, 2019, 139, 2238-2255.	1.6	54
34	Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial. Pulmonary Circulation, 2019, 9, 204589401987861.	1.7	12
35	Association between lung ultrasound findings and invasive exercise haemodynamics in patients with undifferentiated dyspnoea. ESC Heart Failure, 2019, 6, 202-207.	3.1	12
36	The Tricuspid Valve Relationship WithÂtheÂRight Ventricle and PulmonaryÂVasculature. JACC: Cardiovascular Imaging, 2019, 12, 564-565.	5.3	9

#	Article	IF	Citations
37	Network Analysis to Risk Stratify Patients With Exercise Intolerance. Circulation Research, 2018, 122, 864-876.	4.5	42
38	Impaired systemic oxygen extraction in treated exercise pulmonary hypertension: a new engine in an old car?. Pulmonary Circulation, 2018, 8, 1-4.	1.7	7
39	Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease. Lung, 2018, 196, 139-146.	3.3	15
40	A four-tier classification system of pulmonary artery metrics on computed tomography for the diagnosis and prognosis of pulmonary hypertension. Journal of Cardiovascular Computed Tomography, 2018, 12, 60-66.	1.3	28
41	Right ventriculoâ€“arterial uncoupling and impaired contractile reserve in obese patients with unexplained exercise intolerance. European Journal of Applied Physiology, 2018, 118, 1415-1426.	2.5	6
42	Rationale and design of the ranolazine PHâ€“RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension. Open Heart, 2018, 5, e000736.	2.3	12
43	The Dyspnea Clinic. Circulation, 2018, 137, 1994-1996.	1.6	11
44	Pulmonary Vascular Resistance During Exercise Predicts Long-Term Outcomes in Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2018, 24, 169-176.	1.7	20
45	Ultrasoundâ€assisted catheterâ€directed thrombolysis compared with anticoagulation alone for treatment of intermediateâ€risk pulmonary embolism. Pulmonary Circulation, 2018, 8, 1-7.	1.7	20
46	NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Science Translational Medicine, 2018, 10, .	12.4	89
47	Development of a RightÂVentricular Outflow TractÂGradient During Upright Exercise. Journal of the American College of Cardiology, 2017, 69, 595-597.	2.8	3
48	Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure. Pulmonary Circulation, 2017, 7, 654-665.	1.7	38
49	Invasive cardiopulmonary exercise testing in the evaluation of unexplained dyspnea: Insights from a multidisciplinary dyspnea center. European Journal of Preventive Cardiology, 2017, 24, 1190-1199.	1.8	58
50	Open label study of ambrisentan in patients with exercise pulmonary hypertension. Pulmonary Circulation, 2017, 7, 531-538.	1.7	17
51	Totally Implantable IV Treprostinil TherapyÂin Pulmonary Hypertension Assessment of the Implantation Procedure. Chest, 2017, 152, 1128-1134.	0.8	16
52	Accuracy of Echocardiography to Estimate Pulmonary Artery Pressures With Exercise. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	62
53	Persistence and proliferation of human mesenchymal stromal cells in the right ventricular myocardium after intracoronary injection in a large animal model of pulmonary hypertension. Cytotherapy, 2017, 19, 668-679.	0.7	12
54	Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers. Pulmonary Circulation, 2017, 7, 692-701.	1.7	9

#	Article	IF	Citations
55	Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension. Thrombosis Research, 2017, 160, 83-90.	1.7	7
56	Left ventricular deformation at rest predicts exerciseâ€induced elevation in pulmonary artery wedge pressure in patients with unexplained dyspnoea. European Journal of Heart Failure, 2017, 19, 101-110.	7.1	32
57	PVDOMICS. Circulation Research, 2017, 121, 1136-1139.	4.5	113
58	Hemodynamic and metabolic characteristics associated with development of a right ventricular outflow tract pressure gradient during upright exercise. PLoS ONE, 2017, 12, e0179053.	2.5	9
59	Functional impact of exercise pulmonary hypertension in patients with borderline pulmonary arterial pressure. , 2017, , .		0
60	Prognostic impact of exercise pulmonary hypertension. , 2017, , .		0
61	Changes in Intraparenchymal Arterial and Venous Blood Distribution Quantified From CT Scans in PAH. Chest, 2016, 150, 1175A.	0.8	0
62	Changes in Intraparenchymal Arterial and Venous Blood Distribution Quantified From CT Scans in Pulmonary Hypertension With Elevated Wedge Pressure. Chest, 2016, 150, 1179A.	0.8	1
63	Physiological Techniques and Pulmonary Hypertension â€“ Left Heart Disease. Progress in Cardiovascular Diseases, 2016, 59, 30-41.	3.1	2
64	Pulmonary haemodynamics during recovery from maximum incremental cycling exercise. European Respiratory Journal, 2016, 48, 158-167.	6.7	27
65	Exercise intolerance in pulmonary hypertension: mechanism, evaluation and clinical implications. Expert Review of Respiratory Medicine, 2016, 10, 979-990.	2.5	27
66	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System. Chest, 2016, 150, 27-34.	0.8	48
67	Unexplained Exertional Dyspnea Caused by Low Ventricular Filling Pressures: Results from Clinical Invasive Cardiopulmonary Exercise Testing. Pulmonary Circulation, 2016, 6, 55-62.	1.7	67
68	Pulmonary Vascular Morphology as an Imaging Biomarker in Chronic Thromboembolic Pulmonary Hypertension. Pulmonary Circulation, 2016, 6, 70-81.	1.7	47
69	Upâ€regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. FASEB Journal, 2016, 30, 2511-2527.	0.5	39
70	Age-related upper limits of normal for maximum upright exercise pulmonary haemodynamics. European Respiratory Journal, 2016, 47, 1179-1188.	6.7	72
71	Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge. Journal of Heart and Lung Transplantation, 2016, 35, 151-164.	0.6	23
72	Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3313-3335.	8.2	303

#	Article	IF	Citations
73	Assessing Disease State in the Pulmonary Vasculature in Clinical Practice and Research. , 2016, , 219-229.		1
74	Initial Data Report from â€œLARIATâ€: A Phase 2 Study of Bardoxolone Methyl in PAH Patients on Stable Background Therapy. Chest, 2015, 148, 639A.	0.8	11
75	Genetic and hypoxic alterations of the micro <scp>RNA</scp> â€210â€•<scp>ISCU</scp> 1/2 axis promote ironâ€“sulfur deficiency and pulmonary hypertension. EMBO Molecular Medicine, 2015, 7, 695-713.	6.9	120
76	Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit. Cell Reports, 2015, 13, 1016-1032.	6.4	193
77	E/eâ€² Ratio in Patients With Unexplained Dyspnea. Circulation: Heart Failure, 2015, 8, 749-756.	3.9	93
78	Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension. Circulation, 2015, 132, 2152-2161.	1.6	10
79	Protocol for Exercise Hemodynamic Assessment: Performing an Invasive Cardiopulmonary Exercise Test in Clinical Practice. Pulmonary Circulation, 2015, 5, 610-618.	1.7	68
80	Central Cardiac Limit to Aerobic Capacity in Patients With Exertional Pulmonary Venous Hypertension. Circulation: Heart Failure, 2015, 8, 278-285.	3.9	58
81	The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension. Journal of Biological Chemistry, 2015, 290, 2069-2085.	3.4	80
82	Improving Decision Making for Massive Transfusions in a Resource Poor Setting: A Preliminary Study in Kenya. PLoS ONE, 2015, 10, e0127987.	2.5	3
83	Safety and Efficacy of Transition from Inhaled Treprostinil to Parenteral Treprostinil in Selected Patients with Pulmonary Arterial Hypertension. Pulmonary Circulation, 2014, 4, 456-461.	1.7	11
84	Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. Journal of Clinical Investigation, 2014, 124, 3514-3528.	8.2	182
85	Conversion From Sildenafil to Tadalafil. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 550-557.	2.0	14
86	Measuring central pulmonary pressures during exercise in COPD: how to cope with respiratory effects. European Respiratory Journal, 2014, 43, 1316-1325.	6.7	80
87	Right heart failure: Toward a common language. Journal of Heart and Lung Transplantation, 2014, 33, 123-126.	0.6	76
88	Towards Widespread Noninvasive Assessment of Pulmonary Vascular Resistance in Clinical Practice. Journal of the American Society of Echocardiography, 2014, 27, 108-109.	2.8	4
89	Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: Initial clinical experience. Journal of Heart and Lung Transplantation, 2013, 32, 381-387.	0.6	114
90	A Simple Echocardiographic Method to Estimate Pulmonary Vascular Resistance. American Journal of Cardiology, 2013, 112, 873-882.	1.6	60

#	Article	IF	Citations
91	Pulmonary Arterial Hypertension: New Insights Into the Optimal Role of Current and Emerging Prostacyclin Therapies. American Journal of Cardiology, 2013, 111, 1A-16A.	1.6	62
92	Effectiveness of Spironolactone Plus Ambrisentan for Treatment ofÂPulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials). American Journal of Cardiology, 2013, 112, 720-725.	1.6	92
93	Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension. Journal of Medical Economics, 2013, 16, 298-306.	2.1	22
94	Right Heart Failure: Toward a Common Language. Pulmonary Circulation, 2013, 3, 963-967.	1.7	28
95	Circulating Mitochondrial DNA in Patients in the ICU as a Marker of Mortality: Derivation and Validation. PLoS Medicine, 2013, 10, e1001577.	8.4	354
96	Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension. Circulation, 2013, 127, 563-565.	1.6	7
97	The Invasive Cardiopulmonary Exercise Test. Circulation, 2013, 127, 1157-1164.	1.6	116
98	Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. European Journal of Heart Failure, 2013, 15, 277-283.	7.1	91
99	Phosphodiesterase-5 Inhibitors. Handbook of Experimental Pharmacology, 2013, 218, 229-255.	1.8	5
100	Protocol for Vasoreactivity Testing With Epoprostenol in Pulmonary Hypertension. Critical Pathways in Cardiology, 2012, 11, 40-42.	0.5	7
101	MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension. Circulation, 2012, 125, 1520-1532.	1.6	246
102	Exercise physiology and pulmonary arterial hypertension. Progress in Cardiovascular Diseases, 2012, 55, 172-179.	3.1	41
103	Pulmonary Hypertension in Older Patients. , 2012, , 111-131.		0
104	Circulating endothelial and endothelial progenitor cells in patients with severe sepsis. Microvascular Research, 2011, 81, 216-221.	2.5	30
105	Dysregulation Of Cell Cycle Proteins Is Associated With IL-6 Induced Pulmonary Vascular Remodeling And Pulmonary Arterial Hypertension. , 2011, , .		0
106	Extracellular Atp Triggers Hyperoxia-Induced Lung Inflammation. , 2011, , .		0
107	Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Circulation, 2011, 124, 133-135.	1.6	10
108	Vasoreactivity to Inhaled Nitric Oxide with Oxygen Predicts Longâ€Term Survival in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2011, 1, 250-258.	1.7	49

#	Article	IF	Citations
109	Adherence to Phosphodiesterase Type 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension - A Real-World Analysis. Chest, 2011, 140, 736A.	0.8	1
110	Quanitificaiton Of Number Of Circulating endothelial Cells In Patients With Severe Sepsis. , 2010, , .		0
111	The Inflammasome Mediates Hyperoxia-Induced Alveolar Cell Permeability. Journal of Immunology, 2010, 184, 5819-5826.	0.8	77
112	Noninvasive Assessment of Murine Pulmonary Arterial Pressure. Circulation: Cardiovascular Imaging, 2010, 3, 157-163.	2.6	158
113	Response to Letter Regarding Article, â€œExercise-Induced Pulmonary Arterial Hypertensionâ€. Circulation, 2009, 120, .	1.6	0
114	Review: Portopulmonary hypertension: challenges in diagnosis and management. Therapeutic Advances in Gastroenterology, 2009, 2, 281-286.	3.2	5
115	IL-6 Cytoprotection in Hyperoxic Acute Lung Injury Occurs via Suppressor of Cytokine Signaling-1â€“Induced Apoptosis Signalâ€“Regulating Kinase-1 Degradation. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 314-324.	2.9	45
116	IL-6 Protects against Hyperoxia-Induced Mitochondrial Damage via Bcl-2â€“Induced Bak Interactions with Mitofusions. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 385-396.	2.9	81
117	IL-6 cytoprotection in hyperoxic acute lung injury occurs via PI3K/Akt-mediated Bax phosphorylation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L6-L16.	2.9	52
118	Interleukin-6 Overexpression Induces Pulmonary Hypertension. Circulation Research, 2009, 104, 236-244.	4.5	539
119	Inflammasome: A Pivotal Role in hyperoxiaâ€induced acute lung injury?. FASEB Journal, 2009, 23, 1025.1.	0.5	0
120	The role of ILâ€6 and ILâ€11 in hyperoxic injury in developing lung. Pediatric Pulmonology, 2008, 43, 297-304.	2.0	10
121	Exercise-Induced Pulmonary Arterial Hypertension. Circulation, 2008, 118, 2183-2189.	1.6	318
122	Cicletanine for the Treatment of Pulmonary Arterial Hypertension. Archives of Internal Medicine, 2008, 168, 2164.	3.8	15
123	Multicenter implementation of a consensus-developed, evidence-based, spontaneous breathing trial protocol*. Critical Care Medicine, 2008, 36, 2753-2762.	0.9	48
124	Impaired Systemic Oxygen Extraction at Maximum Exercise in Pulmonary Hypertension. Medicine and Science in Sports and Exercise, 2008, 40, 3-8.	0.4	75
125	Plasma Gelsolin Depletion and Circulating Actin in Sepsisâ€”A Pilot Study. PLoS ONE, 2008, 3, e3712.	2.5	57
126	ILâ€6 Inhibits Hyperoxia Induced Bax Translocation Through Pi3kinase/AKT Mediated Bax Phosphorylation. FASEB Journal, 2008, 22, 1238.4.	0.5	0

#	Article	IF	Citations
127	Plasma gelsolin is a marker and therapeutic agent in animal sepsis*. Critical Care Medicine, 2007, 35, 849-855.	0.9	131
128	TREPROSTINIL SODIUM IMPROVES EXERCISE CAPACITY WHEN ADDED TO EXISTING ORAL PULMONARY ARTERIAL HYPERTENSION THERAPY. Chest, 2007, 132, 474B.	0.8	3
129	MULTICENTER EXPERIENCE WITH THE RAPID TRANSITION TO INTRAVENOUS TREPROSTINIL FROM EPOPROSTENOL IN PULMONARY ARTERIAL HYPERTENSION. Chest, 2007, 132, 635A.	0.8	0
130	Pulmonary Arterial Hypertension: Evaluation and Management. Southern Medical Journal, 2007, 100, 393-399.	0.7	10
131	A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Vascular Health and Risk Management, 2007, 3, 151-7.	2.3	6
132	PREOPERATIVE INTRAVENOUS EPOPROSTENOL PRIOR TO SURGICAL REPAIR OF A VENTRICULAR SEPTAL DEFECT IN AN ADULT WITH EISENMENGER SYNDROME. Chest, 2006, 130, 305S.	0.8	0
133	Conversion to Bosentan From Prostacyclin Infusion Therapy in Pulmonary Arterial Hypertension. Chest, 2006, 130, 1471-1480.	0.8	42
134	DNA Damage Induced by Hyperoxia. American Journal of Respiratory Cell and Molecular Biology, 2006, 35, 277-288.	2.9	58
135	TREATMENT OF PORTOPULMONARY HYPERTENSION: EXPERIENCE WITH SILDENAFIL. Chest, 2006, 130, 256S.	0.8	0
136	Modulation of IGF-Binding Protein-2 and -3 in Hyperoxic Injury in Developing Rat Lung. Pediatric Research, 2005, 58, 222-228.	2.3	14
137	Bcl-2â€“related protein A1 is an endogenous and cytokine-stimulated mediator of cytoprotection in hyperoxic acute lung injury. Journal of Clinical Investigation, 2005, 115, 1039-1048.	8.2	85
138	LOW PLASMA GELSOLIN LEVEL IN SEPSIS IS ASSOCIATED WITH INCREASED MORTALITY.. Critical Care Medicine, 2005, 33, A163.	0.9	0
139	Roundtable debate: Controversies in the management of the septic patient--desperately seeking consensus. Critical Care, 2004, 9, E1.	5.8	7
140	Pulmonary hypertension: work in progress. Journal of Nuclear Cardiology, 2003, 10, 413-423.	2.1	3
141	Case 14-2003. New England Journal of Medicine, 2003, 348, 1902-1912.	27.0	7
142	Interleukin-11 and Interleukin-6 Protect Cultured Human Endothelial Cells from H2O2-Induced Cell Death. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 513-522.	2.9	82
143	PULMONARY FUNCTION TEST ABNORMALITIES IN PULMONARY VASCULAR DISEASE AND CHRONIC HEART FAILURE. Clinics in Chest Medicine, 2001, 22, 751-758.	2.1	18
144	Interleukin-6â€“Induced Protection in Hyperoxic Acute Lung Injury. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 535-542.	2.9	209

#	Article	IF	Citations
145	IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. Journal of Clinical Investigation, 2000, 106, 783-791.	8.2	150
146	Targeted Lung Expression of Interleukin-11 Enhances Murine Tolerance of 100% Oxygen and Diminishes Hyperoxia-Induced DNA Fragmentation. Chest, 1999, 116, 8S-9S.	0.8	45
147	Cytomegalovirus as a Pulmonary Pathogen. Chest, 1997, 112, 861.	0.8	0
148	Cytomegalovirus as a Primary Pulmonary Pathogen in AIDS. Chest, 1997, 111, 128-134.	0.8	51
149	Electromechanical Dissociation following Verapamil and Propranolol Ingestion: A Physiologic Profile. Cardiology, 1997, 88, 478-481.	1.4	5